Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
|Articles|December 26, 2020
The Top 5 News and Updates in Acute Myeloid Leukemia That Patients May Have Missed in 2020
Author(s)CURE staff
A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.
Advertisement
There have been several updates in the field of acute myeloid leukemia in 2020. Here, CURE® looks back at some of the top news and updates in this field that patients read the most.
- Patients with acute myeloid leukemia (AML) often have to undergo transplant during treatment but are susceptible to other side effects, but new research indicates that the use of immunotherapy after these treatments can improve patient outcomes.
READ MORE .
- Patients with AML whose disease has relapsed or become resistant to treatment saw a benefit with a combination of Opdivo and Vidaza.
READ MORE . - The COVID-19 pandemic has created a unique challenge for patients with myelodysplastic syndromes and AML, creating many questions that experts tried to answer in an April webinar from The Aplastic Anemia and MDS International Foundation.
READ MORE . - Adding Venclexta (venetoclax) to Vidaza (azacitadine) chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.
READ MORE . - A feature in CURE®’s Hematology special issue in March analyzed a wave of new targeted therapies expanding the options in AML.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.
A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.
For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.
Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
4
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
5